Welcome to our dedicated page for Regencell Bioscience Holdings SEC filings (Ticker: RGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Regencell Bioscience Holdings Limited (NASDAQ: RGC) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures, including Form 6‑K current reports and other documents filed as a foreign private issuer. Regencell is an early-stage bioscience company that focuses on Traditional Chinese Medicine (TCM) formulae for ADHD, ASD and infectious diseases affecting the immune system, and its filings offer insight into how this strategy is reflected in its governance, financial reporting and material events.
Through its Form 6‑K submissions, Regencell furnishes information such as unaudited condensed consolidated interim financial statements, management financial results for specific periods, and board and committee changes. For example, the company has reported the appointment and resignation of independent directors, including details on committee roles and confirmation that certain resignations were not due to disagreements over operations, policies or practices. These filings help investors understand the composition of the audit, compensation and nominating and corporate governance committees that oversee the company’s activities.
Regencell’s filings also reference Schedule 13D reports filed by its Chairman and Chief Executive Officer, documenting open-market purchases of ordinary shares and resulting ownership levels. While the Schedule 13D forms themselves are filed separately, company press releases and 6‑K reports highlight these insider transactions, which some investors track to gauge management’s alignment with shareholders.
On Stock Titan, each new Regencell filing is captured in near real time from the SEC’s EDGAR system. AI-powered summaries are provided to explain the key points of lengthy documents in plain language, helping readers quickly identify items such as changes in director appointments, committee assignments, and furnished financial data. Users can review historical 6‑K submissions and related exhibits to follow Regencell’s evolution as an early-stage TCM-focused bioscience company, while AI-generated overviews reduce the time needed to interpret complex regulatory text.
Regencell Bioscience Holdings Limited furnished a Form 6-K to add key legal documents into its existing U.S. securities registration materials. The filing incorporates a Form F-3 registration statement and related prospectus supplement by reference.
The 6-K attaches a form of sales agreement with Univest Securities, LLC, a Cayman Islands tax opinion from Ogier (Cayman) LLP, and Ogier’s related consent. These exhibits become part of the company’s Form F-3 and prospectus supplement once this report is furnished.
Regencell Bioscience Holdings Limited has established an at-the-market equity offering program allowing it to offer and sell up to $500,000,000 of its ordinary shares from time to time. The shares will be issued under an automatically effective shelf registration statement on Form F-3.
The company entered into a sales agreement with Univest Securities, LLC as sales agent, which will use commercially reasonable efforts to sell shares on Nasdaq or via other permitted methods at prevailing market prices. Regencell currently intends to use any net proceeds primarily for working capital, capital expenditures and general corporate purposes.
Regencell Bioscience Holdings Limited proposes an at-the-market offering of up to $500,000,000 of Ordinary Shares through Univest Securities, LLC as sales agent under a Sales Agreement dated March 30, 2026. Sales may occur from time to time on Nasdaq or by other at-the-market methods at prevailing market prices.
The prospectus supplement states 494,488,908 Ordinary Shares were outstanding prior to this offering and illustrates an example where sales of up to $500,000,000 at an assumed price of $25.67 per share would increase shares outstanding to up to 513,966,897. Net proceeds are intended for working capital, capital expenditures and general corporate purposes. The filing discloses material risks including potential dilution, PFIC tax treatment for U.S. holders for the year ended June 30, 2025, and an auditor’s going-concern explanatory paragraph.
Regencell Bioscience Holdings Ltd reported the initial holdings of director Dr. William Wing Yan Lo on a Form 3. The filing shows he holds a stock option to purchase 592,230 ordinary shares at an exercise price of $0.84 per share.
The option was granted on January 1, 2022 under the company’s 2021 Share Option Plan, vested in equal installments over four anniversaries of the grant date, and is now fully vested. The option expires on December 31, 2032. The Form 3 reflects existing derivative holdings rather than a new market buy or sell.
Regencell Bioscience Holdings Ltd director Margaret Hoor Han Lo has filed an initial ownership report showing her equity position in the company. She directly holds 604,050 ordinary shares. She also holds a stock option to purchase 592,230 ordinary shares at an exercise price of $17.40 per share, expiring on June 29, 2035. According to the disclosure, this option was granted on June 30, 2025 under the company’s 2021 Share Option Plan and vests in four equal annual installments on each anniversary of the grant date. The filing does not record any new purchases or sales, only the existing holdings and option grant terms.
Regencell Bioscience Holdings Ltd director Evana Yee Wah Hui has reported her initial ownership of a stock option position in a Form 3 filing. The option gives her the right to purchase up to 592,230 ordinary shares at an exercise price of $0.2500 per share.
The option was granted on June 9, 2021 under the company’s 2021 Share Option Plan. It vested in equal portions on each of the four anniversaries of the closing of Regencell’s initial public offering and is now fully vested. The expiration date is 10 years from the dates the options became vested.
Regencell Bioscience Holdings Ltd filed an initial ownership report for its Financial Controller, Chan Ho Yau, showing a stock option position. The option covers 740,278 underlying ordinary shares at an exercise price of $0.2500 per share. It was granted on June 9, 2021 under the 2021 Share Option Plan, vested in four equal installments on each anniversary of the company’s initial public offering closing, is now fully vested, and will expire 10 years after the options become vested.
Regencell Bioscience Holdings Ltd director and officer James Wai Hong Chung filed an initial statement of beneficial ownership showing a stock option to purchase 11,844,258 ordinary shares at an exercise price of $0.2500 per share. The option was granted on June 9, 2021 under the 2021 Share Option Plan, vested in four equal annual installments after the company’s IPO closing, and is now fully vested.
Regencell Bioscience Holdings Ltd Chief Business Officer Au Yat-Pui filed a Form 3 reporting beneficial ownership of 581,514 ordinary shares held directly. The filing is an ownership disclosure and does not report any new share purchases or sales.
Regencell Bioscience Holdings Ltd director and Chief Executive Officer Au Yat-Gai filed an initial ownership report showing indirect control over 437,896,116 ordinary shares. This includes 426,429,198 shares held by Regencell (BVI) Limited and 11,466,918 shares held by his spouse, which he may be deemed to beneficially own.